Value Creation Story

Challenging to continue contributing to patients throughout a history of over 100 years

Daiichi Sankyo continues to challenge the creation of innovative pharmaceuticals by leveraging the strengths of Science & Technology (S&T) that have been passed down over a long period of 100 years. Moving forward, we will continue to create innovative pharmaceuticals sourced from S&T, addressing the unmet medical needs of each era, and "contributing to the enrichment of quality of life around the world" through the realization of our 2030 Vision.

History as a pharma innovator (major products over the years)

1899

Launched Taka-Diastase®, a digestive enzyme agent 1902

Adrenalin, an adrenal cortex hormone agent

1915

Began domestic manufacturing of Salvarsan, a therapeutic drug for syphilis

1922

Began manufacturing of Bosmin®, a vasoconstriction/ hemostasis and asthma medicine

1951

Manufactured Chloromycetin[®], the first antibiotic produced in Japan

1965

Transamin[®], a hemostatic and anti-inflammatory agent

1985

Tarivid®, a broad-spectrum oral antimicrobial agent


1986 Loxonin[®], an anti-inflammatory analgesic

1989 Mevalotin®, hypercholesterolemia treatment

1993 Cravit[®], a broad-spectrum oral antimicrobial agent

2002 Olmesartan (Olmetec. in Japan and Europe, Benicar. in the United States), an antihypertensive agent

Our 5-year business plan



Breakthrough proprietary products that address "the unmet medical needs" of each era.

Infectious diseases (tuberculosis and pneumonia)	Lifestyle-related diseases	Cancer, dementia, and emerg
	• 2009 Efient [®] an antiplatelet agent • 2010 • 2011 Inavir [®] , anti-influenza treatment • 2011	• 2019 Tarlige [®] , pain treatment • 2020 Enhertu [®] , an anti-cancer a directed antibod

Innovator with a competitive advantage in oncology," and shift to further growth toward

2030 Vision

Innovative Global Healthcare Company **Contributing to** the Sustainable Development of Society

erging and re-emerging infectious diseases

• 2023

er agent (HER2 ody drug conjugate)

DAICHIRONA® for intramuscular injection vaccine against COVID-19